razoxane has been researched along with atrial natriuretic factor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Garami, M; Gardner, DG | 1 |
| Brandt, A; Ebner, A; Ebner, B; Forkmann, M; Hofmann, A; Morawietz, H; Polanski, AK; Steinbronn, N; Strasser, RH; Tausche, AK; Wunderlich, C | 1 |
2 other study(ies) available for razoxane and atrial natriuretic factor
| Article | Year |
|---|---|
Doxorubicin selectively inhibits brain versus atrial natriuretic peptide gene expression in cultured neonatal rat myocytes.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Agents; Atrial Natriuretic Factor; Cardiovascular Agents; Cell Survival; Cells, Cultured; Dactinomycin; Dose-Response Relationship, Drug; Doxorubicin; Gene Expression; Heart Atria; Natriuretic Peptide, Brain; Probucol; Promoter Regions, Genetic; Protein Synthesis Inhibitors; Rats; Razoxane; RNA, Messenger; Transfection | 1999 |
Dexrazoxane prevents the development of the impaired cardiac phenotype in caveolin-1-disrupted mice.
Topics: Animals; Apoptosis; Atrial Natriuretic Factor; Cardiomyopathies; Cardiovascular Agents; Caveolin 1; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase; Phenotype; Razoxane; Reactive Oxygen Species; Treatment Outcome; Ventricular Function, Left | 2013 |